Promoting Me-Too Biologicals: Portfolio vs. Single Product Approach
Executive Summary
Novo Nordisk's grand plan for pitting its new basal insulin Levemir against Aventis' dominant Lantus is to promote the product in the context of the company's broader insulin portfolio. Novo believes its portfolio approach should capture a greater overall share of the insulin space than Aventis with its one-size-fits-all strategy.You may also be interested in...
Antegren: Shaking Up the MS Market?
Antegren: Shaking Up the MS Market?
Aventis: Building on a Base in Diabetes
Need a specific report? 1000+ reports available
Buy Reports